9b01: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "9b01" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
==Catalytic mutant C357A nnhA in CHES buffer== | |||
<StructureSection load='9b01' size='340' side='right'caption='[[9b01]], [[Resolution|resolution]] 1.99Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[9b01]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_sp._JS330 Mycobacterium sp. JS330]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9B01 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9B01 FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.99Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=FMT:FORMIC+ACID'>FMT</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9b01 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9b01 OCA], [https://pdbe.org/9b01 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9b01 RCSB], [https://www.ebi.ac.uk/pdbsum/9b01 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9b01 ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/NNHA_MYCS0 NNHA_MYCS0] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The antibiotic 2-nitroimidazole (2NI) or azomycin, used for treating drug-resistant tuberculosis and imaging tumor hypoxia, requires activation by bacterial nitroreductases for its antibiotic and cytotoxic effect. Mycobacterium sp. JS330 produces 2-nitroimidazole nitrohydrolase (NnhA) that circumvents 2NI activation, conferring 2NI resistance by hydrolysing it to nitrite and imidazol-2-one (IM2O) instead. This study elucidates NnhA's structure, catalytic mechanism, and evolutionary background within the guanidino-group modifying enzyme (GME) superfamily, aided by a more soluble protein variant engineered through directed evolution. Despite low sequence similarity and limited occurrence in a few soil-dwelling mycobacteria and Actinomycetota, NnhA maintains the alpha/beta propeller fold characteristic of GME superfamily enzymes and forms an unusual hexameric ring structure formed by a trimer of domain-swapped dimers. The similarity of its active site to arginine deiminases (ADIs) and human dimethylarginine dimethylaminohydrolases (DDAHs), along with molecular dynamics simulations, suggests NnhA's catalytic mechanism resembles the hydrolysis reactions of these related enzymes. | |||
Structural insights into the enzymatic breakdown of azomycin-derived antibiotics by 2-nitroimdazole hydrolase (NnhA).,Ahmed FH, Liu JW, Royan S, Warden AC, Esquirol L, Pandey G, Newman J, Scott C, Peat TS Commun Biol. 2024 Dec 19;7(1):1676. doi: 10.1038/s42003-024-07336-6. PMID:39702827<ref>PMID:39702827</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 9b01" style="background-color:#fffaf0;"></div> | ||
[[Category: Newman | == References == | ||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Mycobacterium sp. JS330]] | |||
[[Category: Newman J]] | |||
[[Category: Peat TS]] | |||
Latest revision as of 14:01, 1 January 2025
Catalytic mutant C357A nnhA in CHES buffer
| ||||||||||||
